The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
This trial has been completed.
|Conditions||diabetes, type 1 diabetes|
|Treatment||alpha 1-antitrypsin (aat, aralast np)|
|Sponsor||University of Colorado, Denver|
|Collaborator||Omni Bio Pharmaceutical, Inc.|
|Start date||October 2010|
|End date||October 2015|
|Trial size||12 participants|
|Trial identifier||NCT01319331, 09-0667|
The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
|Intervention model||single group assignment|
Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
To assess participant safety & feasibility of study drug administration
time frame: Study duration is 2 years
To assess AAT treatment on the maintenance of c-peptide production
time frame: Stimulated c-peptide at year one and two.
Assess the effects of AAT on glycemic variability and A1c.
time frame: Continuous Glucose Monitoring at one and two years.
All participants from 6 years up to 45 years old.
Inclusion Criteria: - Diagnosis of Type 1 Diabetes Mellitus based on ADA Criteria for fewer than 5 years but more than 100 days - 6-45 years of age, inclusive. To assess safety, we will initially enroll 8 patients over the age of 16. Following the last infusion of the 8th patient, we will assess adverse events. As long as there are no stopping criteria met for these 8 patients we will decrease the age criteria down to 6 years old. - C-peptide increase during screening mixed meal tolerance test with a minimal stimulated value of ≥ 0.2 pmol/mL. - Positive for antibodies to insulin (if insulin autoantibody positive only, determination must be within two weeks of insulin initiation), GAD-65, IA-2 or ZnT8 - Agree to intensive management of diabetes with an HgbA1c goal of < 7.0% - If female, (a) surgically sterile or (b) postmenopausal or (c) if of reproductive potential, willing to use medically acceptable birth control (e.g. female hormonal contraception, barrier methods or sterilization. ) until 3 months after completion of any treatment period - If male and of reproductive potential, willing to use medically acceptable birth control until 3 months after completion of any treatment period, unless the female partner is postmenopausal or surgically sterile - Serum creatinine ≤ 1.5 x upper limit of normal - AST < 2 times the upper limit of normal - Hematology:WBC > 3000 x 109/L; platelets > 100 x 109/L; hemoglobin > 10.0 g/dL. Exclusion Criteria: - Unable or unwilling to comply with the requirements of the study protocol - Body Mass Index (BMI) > 30 kg/m2 - Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days - Previous immunotherapy for T1D - Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days of screening, unless approved by the study PI - History of any organ transplant, including islet cell transplant - Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid arthritis) - Serum bilirubin > ULN, except those subjects whose abnormal values were attributed to any stable, benign condition (such as Gilbert's Syndrome) may be included - TSH outside the normal range at screening, except those subjects on stable doses of thyroid hormone replacement therapy may be included - Known HIV positivity, active hepatitis B or active hepatitis C infection - Anticipated pregnancy during active dosing or within 3 months after completion of active dosing phase - History of a malignant neoplasm within the previous 5 years (except in situ cervical cancer and curable non-melanoma skin malignancy) - Any social condition or medical condition that would, in the opinion of the investigator, prevent complete participation in the study or that would pose a significant hazard to the subjects' participation - History of active substance abuse within 12 months of screening - A psychiatric or medical disorder that would prevent giving informed consent - Individuals with a history of IgA deficiency - Individuals with a history of hypersensitivity to AAT
|Official title||The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide|
|Principal investigator||Peter A Gottlieb, MD|
Call for more information